Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
View Older Stories View More Recent Stories
-
Canaccord Adams Reiterates a 'Hold' on Mosaic (MOS), Lowers Price Target
-
Canaccord Adams Reiterates a 'Buy' on Potash (POT), Lowers Price Target
-
Canaccord Adams Maintains 'Buy' Rating on DexCom (DXCM), Lowers Price Target
-
Canaccord Adams Maintains a 'Buy' on BioMimetic Therapeutics (BMTI), Drops Price Target
-
Canaccord Adams Maintains 'Hold' Rating on Amylin Pharmaceuticals (AMLN), Lowers Price Target
-
Canaccord Adams Reiterates 'Buy' Rating on Optimer Pharmaceuticals (OPTR), Raises Price Target
-
Canaccord Adams Downgrades Thompson Creek Metals (TC) to Hold
-
Canaccord Adams Maintains a 'Buy' Rating on Wright Medical Group (WMGI), Lowers Price Target
-
Unusual 11 Mid-Day Movers 11/03: STEM, HIG, EYE, TVL Higher; VSE, ATRC, NSTC, FIG Lower
-
Canaccord Adams Downgrades AtriCure (ATRC) to Hold
-
Canaccord Adams Reiterates a 'Buy' on Thoratec (THOR)
-
Canaccord Adams Upgrades Agnico-Eagle Mines (AEM) to Buy
-
Canaccord Adams Maintains a 'Buy' Rating on First Solar (FSLR), Raises Price Target
-
Canaccord Adams Maintains 'Hold' on Garmin Ltd. (GRMN), Lowers Price Target
-
Canaccord Adams Maintains a 'Buy' on Texas Instruments (TXN), Adds to Best Ideas List
-
Canaccord Adams Maintains a 'Buy' on Linear Technology (LLTC), adds to Best Ideas List
-
Canaccord Adams Maintains a 'Sell' Rating on Baidu (BIDU), Lowers Price Target
-
Canaccord Adams Upgrades Open Text (OTEX) to Buy
-
Canaccord Adams Downgrades Microsoft (MSFT), Citing Aggressive Street Estimates and Competition
-
Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy
-
Canaccord Adams Upgrades Comverse Technology (CMVT) to Hold
-
Unusual 11 Mid-Day Movers 10/14: XL, NCC, HBAN, KEY Higher; ES, RBS, PIR, DPZ Lower
-
Canaccord Adams Reiterates a 'Buy' Rating on Rackable Systems (RACK), Lowers Earnings Estimates
-
Canaccord Adams Reiterates a 'Hold' Rating on Maxim Integrated Products (MXIM), Lowers Price Target to $15
-
Canaccord Adams Upgrades St. Jude Medical (STJ) to Buy
-
Notable Analyst Rating Changes 10/14: MMC, V, CMA, MMM Upgraded; BUCY, AA, JASO, ABFS Downgraded
-
Canaccord Adams Downgrades JA Solar (JASO) to Hold
-
Canaccord Adams Maintains 'Buy' Rating on VALE (RIO), but Lowers Price Target
-
Canaccord Adams Maintains 'Buy' Rating on Thompson Creek Metals (TC)
-
Canaccord Adams Maintains 'Buy' Rating on Taseko Mines Limited (TGB)
-
Canaccord Adams Downgrades Freeport-McMoRan (FCX) to Sell, Slashes Price Target
-
Canaccord Adams Upgrades Cameco (CCJ) to Buy
-
Canaccord Upgrades RIMM to Buy on Unveiling of Storm
-
Canaccord Upgrades Research In Motion (RIMM) to Buy
-
Canaccord Adams Upgrades Amylin Pharmaceuticals (AMLN) to Hold; Competitors on the Way and Safety Issues May Continue to Weigh on Shares
-
Canaccord Adams Initiates Coverage on Baldor Electric (BEZ) with a Buy
-
Canaccord Adams Downgrades Mosaic (MOS) and Agrium (AGU), Slashes Price Targets On Group
-
IBM (IBM) October volatility Elevated at 58
-
Canaccord Adams Slashes Price Target on Garmin (GRMN) to $30
-
Canaccord Adds Orexigen Therapeutics (OREX) to Best Ideas List; $21 PT
-
Research In Motion (RIMM) Slammed After Results; Wall Street Throws In The Towel
-
Canaccord Adams Downgrades Research In Motion (RIMM) to Hold
-
Hansen Natural (HANS) volatility Elevated on wide price movement
-
Analyst Previews Mosaic's (MOS) Q1 Earnings; Reiterates Buy
-
Finance Layoffs Won't Affect Research In Motion's (RIMM) Momentum -Canaccord Adams
-
Canaccord Starts Biovail (BVF) at Buy; $14 PT
-
Canaccord Says Buy Potash (POT) on Recent Weakness
-
Canaccord Reiterates Research In Motion (RIMM) as Top Pick; $185 PT
-
Canaccord Adams Starts Compellent Technologies (CML) at Buy
-
Canaccord Cuts Price Target on Research In Motion (RIMM) to $185

